scholarly journals 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (39) ◽  
pp. 66112-66116 ◽  
Author(s):  
Finn E. von Eyben ◽  
Timo Kiljunen ◽  
Timo Joensuu ◽  
Kalevi Kairemo ◽  
Christian Uprimny ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Metastatic Prostate Cancer ◽  
Radioligand Therapy

scholarly journals 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

Oncotarget ◽  
2019 ◽  
Vol 10 (25) ◽  
pp. 2451-2461 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Aviral Singh ◽  
Jingjing Zhang ◽  
Karin Nipsch ◽  
Danielle Meyrick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Metastatic Prostate Cancer ◽  
Radioligand Therapy

scholarly journals Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

2021 ◽  
Vol 62 (6) ◽  
pp. 650
Author(s):  
William John Yaxley ◽  
Rhiannon McBean ◽  
David Wong ◽  
David Grimes ◽  
Paul Vasey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Metastatic Prostate Cancer ◽  
Prostate Specific Membrane Antigen ◽  
Radioligand Therapy ◽  
Specific Membrane

scholarly journals Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e042953
Author(s):  
Martin John Connor ◽  
Taimur Tariq Shah ◽  
Katarzyna Smigielska ◽  
Emily Day ◽  
Johanna Sukumar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Randomised Controlled Trial ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Controlled Trial ◽  
Pelvic Lymph Node ◽  
Study Results ◽  
Randomised Controlled

IntroductionSurvival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone.MethodsA phase II, prospective, multicentre, three-arm randomised controlled trial incorporating an embedded feasibility pilot. All men with new histologically diagnosed, hormone-sensitive, metastatic prostate cancer, within 4 months of commencing ADT and of performance status 0 to 2 are eligible. Patients will be randomised to Control (standard of care (SOC)) OR Intervention 1 (minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)) OR Intervention 2 (cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)). Metastatic burden will be prespecified using the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) definition. Men with low burden disease in intervention arms are eligible for metastasis-directed therapy, in the form of stereotactic ablative body radiotherapy (SABR) or surgery. Standard systemic therapy will be administered in all arms with ADT±upfront systemic chemotherapy or androgen receptor agents. Patients will be followed-up for a minimum of 2 years. Primary outcome: PFS. Secondary outcomes include predictive factors for PFS and overall survival; urinary, sexual and rectal side effects. Embedded feasibility sample size is 80, with 918 patients required in the main phase II component. Study recruitment commenced in April 2019, with planned follow-up completed by April 2024.Ethics and disseminationApproved by the Health Research Authority (HRA) Research Ethics Committee Wales-5 (19/WA0005). Study results will be submitted for publication in peer-reviewed journals.Trial registration numberNCT03763253; ISCRTN58401737

Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer

The Prostate ◽  
2010 ◽  
Vol 70 (10) ◽  
pp. 1110-1118 ◽  
Author(s):  
David Schilling ◽  
Joerg Hennenlotter ◽  
Karl Sotlar ◽  
Ursula Kuehs ◽  
Erika Senger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Tumor Cell ◽  
Single Cell ◽  
Metastatic Prostate Cancer

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

2021 ◽  
Author(s):  
Elahe Mahmoudi ◽  
Elahe Pirayesh ◽  
Mohammad Reza Deevband ◽  
Mahasti Amoui ◽  
Mehrdad Ghorbani Rad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Patient Specific ◽  
Radioligand Therapy

Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

2016 ◽  
Vol 43 (12) ◽  
pp. 835 ◽  
Author(s):  
Hojjat Ahmadzadehfar ◽  
Markus Essler ◽  
Michael Schäfers ◽  
Kambiz Rahbar
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Clinical Use ◽  
Radioligand Therapy

scholarly journals Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Hojjat Ahmadzadehfar ◽  
Kambiz Rahbar ◽  
Stefan Kürpig ◽  
Martin Bögemann ◽  
Michael Claesener ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Metastatic Prostate Cancer ◽  
Radioligand Therapy ◽  
Centre Study ◽  
First Results ◽  
Castrate Resistant

Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients

2019 ◽  
Vol 5 (3) ◽  
pp. 381-388 ◽  
Author(s):  
Marco Bandini ◽  
Felix Preisser ◽  
Sebastiano Nazzani ◽  
Michele Marchioni ◽  
Zhe Tian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Survival Outcomes

scholarly journals Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer

2020 ◽  
Vol 9 (18) ◽  
pp. 6629-6637
Author(s):  
Keisuke Tsuchida ◽  
Koji Inaba ◽  
Tairo Kashihara ◽  
Naoya Murakami ◽  
Kae Okuma ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Clinical Outcomes ◽  
Metastatic Prostate Cancer ◽  
Pelvic Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document